Inflammatix is a technology company.
Inflammatix has raised $57.0M across 1 funding round.
Inflammatix has raised $57.0M in total across 1 funding round.
Inflammatix has raised $57.0M in total across 1 funding round.
Inflammatix's investors include Ahren Innovation Capital, Alumni Ventures, Khosla Ventures, Moonstone Venture Capital, Refactor Capital, The Longevity Fund.
Inflammatix is a molecular diagnostics company headquartered in Sunnyvale, California, developing AI-powered, host-response-based tests to rapidly diagnose acute infections like pneumonia and sepsis in emergency departments.[1][2][3] Its flagship product, the TriVerity™ Test System, is the first FDA-cleared molecular blood test that distinguishes bacterial vs. viral infections and assesses illness severity, enabling faster triage and better patient outcomes for acutely ill adults.[2][3][5] By decoding immune response signatures via mRNA profiles from circulating immune cells, Inflammatix addresses the limitations of pathogen-targeting tests, which often fail due to low bloodstream penetration of infections.[1][6] The company serves emergency and critical care providers, tackling high sepsis mortality and healthcare costs through precision medicine at the point of care, with recent hospital adoption accelerating growth.[3][8]
Inflammatix emerged from Stanford University research, with co-founders Tim Sweeney, MD, PhD (CEO, emergency physician) and Purvesh Khatri, PhD (Chief Scientist, Stanford Medicine Professor) licensing patent-pending immune response biomarkers.[1][3] The idea stemmed from over a decade of Khatri's data science work applying machine learning to immune profiles, revealing insights into infections beyond traditional pathogen tests.[3][6] Initially focused on TriVerity for emergency department use in acute infection and sepsis, the company gained early validation through FDA Breakthrough Device Designation in 2023 and 510(k) clearance in January 2025.[3][5][7] Pivotal moments include the SEPSIS-SHIELD study (over 1,200 patients) published in *Nature Medicine* in September 2025, confirming TriVerity's high sensitivity/specificity, alongside consensus frameworks redefining sepsis as immunological states.[5]
Inflammatix rides the wave of AI-driven precision diagnostics in emergency medicine, shifting from outdated "septic or not" labels to molecular immune profiling amid rising sepsis burdens (high mortality/costs).[3][5] Timing aligns with post-pandemic emphasis on rapid triage, FDA support for breakthroughs, and *Nature Medicine* validations establishing sepsis as treatable immunological states rather than billing codes.[5] Market forces like antimicrobial resistance and hospital resource strains favor its point-of-care speed/accuracy, influencing ecosystems by setting standards for host-response tech and enabling resilient health systems.[1][3] As medtech scales (e.g., new COO for national rollout), it accelerates AI bioinformatics in critical care, potentially cutting billions in sepsis expenses.[8]
With FDA clearance, landmark publications, and operational hires like COO Martín Vazquez, Inflammatix is primed for U.S. hospital scale-up of TriVerity, targeting widespread emergency department adoption.[5][8] Next steps include pipeline expansion (e.g., tropical infections, transplants) and international growth, shaped by AI advancements in immune decoding and consensus frameworks like HI-DEF.[1][5] Its influence could evolve from niche innovator to ecosystem leader, redefining acute care like troponin did for heart attacks—delivering the clarity that transforms emergency triage into precision medicine.[1][3]
Inflammatix has raised $57.0M across 1 funding round. Most recently, it raised $57.0M Series E in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $57.0M Series E | Ahren Innovation Capital, Alumni Ventures, Khosla Ventures, Moonstone Venture Capital, Refactor Capital, The Longevity Fund |